Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | MVD | P53602 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11952582 | 0.89 | BTN3A1 (0.38) | SAT1BTN3A1MVD | |
| Pent-4-Ynyl Diphosphate SCHEMBL1652909 | 0.85 | BTN3A1 (0.46) | BTN3A1LPAR3LPAR1LPAR2MVD | |
| SCHEMBL14816068 | 0.80 | BTN3A1 (0.44) | BTN3A1LPAR3LPAR1LPAR2MVD | |
| SCHEMBL12091539 | 0.79 | SAT1 (0.44) | SAT1LPAR3LPAR1LPAR2CYP2D6 | |
| SCHEMBL26334857 | 0.79 | CYP2D6 (0.39) | LPAR3LPAR1LPAR2CYP2D6CYP3A4 | |
| SCHEMBL11952601 | 0.77 | ACHE (0.41) | SAT1BTN3A1 | |
| SCHEMBL26334858 | 0.77 | CYP2D6 (0.42) | LPAR3LPAR1LPAR2CYP2D6CYP3A4 | |
| SCHEMBL26334849 | 0.77 | CYP2D6 (0.42) | LPAR3LPAR1LPAR2CYP2D6CYP3A4 | |
| SCHEMBL11952605 | 0.77 | SAT1 (0.42) | SAT1BTN3A1LPAR3LPAR1LPAR2 | |
| SCHEMBL26334850 | 0.77 | CYP2D6 (0.42) | LPAR3LPAR1LPAR2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | COASY, FADS2, FDPS | SAT1 2039/4885BTN3A1 4124/4885LPAR3 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.